Drug Trial Radar · NCT06153342
A Study of TL-925 for the Treatment of Allergic Conjunctivitis
Last checked: Nov 19, 2026Latest source record: Dec 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
70
Planned (sponsor's estimate)
Start
Nov 2023
Primary completion
Jan 2024
Study completion Jan 2024
Sponsor
- Lead sponsor
- Telios Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this prospective Phase 2, single-center, randomized, double-masked, placebo-controlled study, approximately 70 subjects with allergic conjunctivitis will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Conditions
- Allergic Conjunctivitis
Interventions
TL-925Drug
TL-925 is an eye drop.
PlaceboDrug
The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular itchingTime frame: 3, 5 and 7 minutes after CAC
- Conjunctival rednessTime frame: 7, 15 and 20 minutes after CAC
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Andover Eye Associates
Andover, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.